Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis (Q42200749)

18 October 2017

Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis (English)

1 reference

18 October 2017

Ussery FM 3rd

1

1 reference

18 October 2017

Gibson SR

2

1 reference

18 October 2017

Conklin RH

3

1 reference

18 October 2017

Piot DF

4

1 reference

18 October 2017

Stool EW

5

1 reference

18 October 2017

Conklin AJ

6

1 reference

18 October 2017

1 May 1988

1 reference

18 October 2017

1 reference

18 October 2017

95

1 reference

18 October 2017

5

1 reference

18 October 2017

640-648

1 reference

Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS.

18 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Ophthalmoscopic and histologic findings in cytomegalovirus retinitis treated with BW-B759U

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Acquired immune deficiency syndrome. Ocular manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Ophthalmic Involvement in Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

9-(1,3-Dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Treatment of cytomegalovirus retinopathy with ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Treatment of cytomegalovirus retinitis with ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U)

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Treatment of cytomegalovirus optic neuritis with dihydroxy propoxymethyl guanine.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Intravitreal toxicity of hydroxyacyclovir (BW-B759U), a new antiviral agent

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Ophthalmologic findings in acquired immune deficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Culture-proven Cytomegalovirus Retinitis in a Homosexual Man with the Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Cytomegalovirus retinitis in a young homosexual male with acquired immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Ocular Disorders Associated with a new Severe Acquired Cellular Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Microvascular aspects of acquired immune deficiency syndrome retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG)

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Stimulation of Cellular Thymidine Kinases by Human Cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

BW B759U for cytomegalovirus retinitis: intraocular drug penetration

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

Rhegmatogenous Retinal Detachment Complicating Cytomegalovirus Retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2888%2933147-7

7 January 2021

10.1016/S0161-6420(88)33147-7

Identifiers

DOI

1 reference

18 October 2017

1 reference